International Biotechnology Trust plc ("IBT") is an investment trust company listed on the London Stock Exchange which invests in companies within the biotechnology sector. The portfolio aims to capture the best chances of clinical, regulatory and commercial success from a diversified portfolio of public and private biotechnology investments.
The ticker for IBT is IBT.L. The unaudited net asset value and yesterday's closing share price can be seen at the top of this page.
The Company’s investment objective is to achieve long-term capital growth by investing in development stage biotechnology companies that are either quoted or unquoted with the potential for high growth. The Company invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
30 June 2010
Celgene to Acquire Abraxis BioScience
25 June 2010
Gilead to Buy CGI Pharmaceuticals for $120 Million
22 June 2010
Pharmaxis Announces Results For Second Phase Iii Trial Of Bronchitol In Cystic Fibrosis